Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $248K fell 18.4% year over year, ahead of the -29.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -7.2% a year.
Context
- Depreciation & amortization amounted to 0.7% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -18.4% holds above the trailing-twelve-month pace of -29.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.34M USD
- Year-over-year change
- -14.4%
- 4-year CAGR
- +3.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.34M | -14.4% |
| FY2024 | 2024-12-31 | 1.56M | -11.1% |
| FY2023 | 2023-12-31 | 1.76M | +5.1% |
| FY2022 | 2022-12-31 | 1.67M | +44.4% |
| FY2021 | 2021-12-31 | 1.16M | — |
Depreciation & Amortization vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's LTM Sep 2026 depreciation & amortization of $1.02M is the 5th largest of the 11 companies compared; the peer median is $705K.
- Its year-over-year change of -29.4% is the 8th highest of 11, against a peer median of +5.2%.
- Depreciation & amortization amounts to 0.4% of revenue for RYTM, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $244.53B | +295495.6% | -7.9% | 23.8% | |
| LTM Jun 2026 | $2.47M | +124.0% | +68.8% | — | |
| LTM Mar 2026 | $2.16M | -28.6% | -14.3% | 10.8% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.64M | +3.3% | +40.6% | 1.7% |
| LTM Sep 2026 | $1.02M | -29.4% | -7.2% | 0.4% | |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Jun 2026 | $450K | +7.1% | +14.0% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $343K | +39.4% | +64.2% | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K | +39.8% | +18.2% | 2.3% |
| LTM Mar 2026 | $98.72K | -65.7% | +26.9% | 0.8% | |
BLTEBelite Bio, Inc | LTM Jun 2026 | $117 | -99.9% | +32.8% | — |
| Peer median (excluding RYTM) | $705K | +5.2% | +26.9% | 2.3% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.61M) | (181.12M) | (184.68M) | (260.6M) | (196.54M) |
| Depreciation & Amortization | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M |
| Deferred Income Tax | (100M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.8M | 19.83M | 32.55M | 39.68M | 66.82M |
| Change in Working Capital | 1.9M | (19.72M) | 4.81M | 10.58M | (968K) |
| Accounts Receivables | (1.25M) | (5.2M) | (8.64M) | (3.65M) | (7.57M) |
| Inventory | (11K) | (2.81M) | (5.71M) | (10.12M) | (7.47M) |
| Accounts Payables | 18.31M | 1.54M | 14.77M | 21.92M | 21.89M |
| Other Working Capital | (15.15M) | (13.26M) | 4.38M | 2.42M | (7.82M) |
| Other Non-Cash Items | (250K) | 5.91M | 9.4M | 94.9M | 13.68M |
| Operating Cash Flow | (146M) | (173.43M) | (136.16M) | (113.88M) | (115.68M) |
| Capital Expenditures | (5.43M) | (4.28M) | (47K) | 0 | (953K) |
| Acquisitions (Net) | 100M | 4M | 0 | 0 | 0 |
| Purchases of Investments | (524.97M) | (251.94M) | (354.92M) | (268.31M) | (348.67M) |
| Sales of Investments | 361.25M | 284.25M | 354.97M | 260.64M | 252.47M |
| Other Investing Activities | 7M | (4M) | (5.67M) | (40.5M) | (40M) |
| Investing Cash Flow | (62.16M) | 28.03M | (5.67M) | (48.17M) | (137.15M) |
| Debt Repayment | 0 | 0 | 0 | (12.9M) | 0 |
| Common Stock Issued | 161.73M | 131.11M | 48.88M | 195.24M | 237.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (3.97M) | 0 |
| Other Financing Activities | 4.76M | 82.72M | 25.49M | 12.87M | (19.92M) |
| Financing Cash Flow | 166.48M | 213.83M | 74.37M | 191.24M | 217.96M |
| Effect of Forex Changes | 0 | 0 | (142K) | 2K | 87K |
| Net Change in Cash | (41.68M) | 68.43M | (67.6M) | 29.19M | (34.78M) |
| Free Cash Flow | (151.44M) | (177.71M) | (136.2M) | (113.88M) | (116.63M) |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.